文献速递血液净化与透析

儿童腹膜透析早期与晚期起始艾考糊精的对比:国际儿科腹膜透析网络研究

Early-Start Versus Late-Start Icodextrin for Children Receiving Chronic Peritoneal Dialysis: Findings from the International Pediatric Peritoneal Dialysis Network.
PubMed 文献 · Clin J Am Soc Nephrol · 2025-09-09

该研究纳入2007至2024年国际儿科腹膜透析网络中21岁以下使用自动腹膜透析并日间留腹的儿童,比较艾考糊精与葡萄糖透析液的效果。结果显示,早期起始艾考糊精(透析开始1年内)可显著改善舒张压标准差评分、延缓残余肾功能下降,并降低技术失败或死亡风险。

要点

  • 早期起始艾考糊精可延缓残余肾功能下降并改善血压控制。
  • 晚期起始艾考糊精者技术失败或死亡风险是早期起始者的5.16倍。
  • 艾考糊精可改善超滤,但腹膜炎率和透析液渗漏与葡萄糖组相似。

核心结论

  • 艾考糊精改善超滤,但仅早期起始相比延迟起始可提高技术生存率、改善血压控制并保护残余肾功能。

研究设计与样本

  • 国际儿科腹膜透析网络2007至2024年纳入21岁以下行自动腹膜透析并日间留腹的儿童,倾向性评分匹配后分析。

主要发现

  • 艾考糊精用于724/3573(20.3%)患者,各地区差异大。
  • 早期起始艾考糊精(透析开始1年内)与舒张压标准差评分下降(β=−1.31,P<0.001)和残余肾功能下降减缓(β=0.11,P=0.002)相关。
  • 晚期起始者(透析≥1年后起始)相比早期起始者,未控制高血压更多(38% vs 20%,P<0.001),降压药需求更高(68% vs 55%,P=0.03),基线透析葡萄糖暴露更高(5.4 vs 4.8 gm/kg/天,P=0.05)。
  • 早期和晚期艾考糊精使用均与超滤持续正性线性增加独立相关(β=0.27和β=0.33,均P<0.01)。
  • 晚期起始者相比早期起始者技术失败/死亡风险显著增加(HR=5.16,95%CI 1.57–17.0,P=0.007)。

临床怎么用

  • 儿童腹膜透析患者可考虑早期(透析开始1年内)起始艾考糊精以改善超滤、血压和残余肾功能。
  • 晚期起始艾考糊精与较高的技术失败或死亡风险相关,应避免延迟起始。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Early icodextrin use preserved residual kidney function and improved BP versus glucose dialysate in pediatric peritoneal dialysis patients. Starting icodextrin within 1 year of commencing peritoneal dialysis reduced the risk of technique failure or death nearly five-fold versus later start. Children younger than 5 years on icodextrin had similar ultrafiltration and BP control with superior kidney function preservation versus older children. BACKGROUND: Experience with icodextrin use in children on long-term peritoneal dialysis (PD) is limited. We describe international icodextrin prescription practices and their effect on clinical outcomes: ultrafiltration, BP control, residual kidney function (RKF), technique and patient survival. METHODS: We included patients younger than 21 years enrolled in the International Pediatric Peritoneal Dialysis Network between 2007 and 2024, on automated PD with a daytime dwell. Outcome analysis was restricted to patients with 6 months or greater follow-up. We used propensity score matching to balance baseline differences between icodextrin and glucose groups. Long-term outcomes and survival were analyzed by longitudinal linear mixed-effects models and Cox proportional hazards models, respectively, adjusting for key covariates. Sensitivity analyses addressed the effect of missing data. RESULTS: Icodextrin was prescribed in 724 of 3573 (20.3%) patients, varying widely across world regions. Only “early-start” icodextrin (within 1 year of PD start) was associated with a significant decline in diastolic BP standard deviation score (β=−1.31, P < 0.001) and a slower decline in RKF (β=0.11, P = 0.002) compared with glucose use alone. “Late-starters” (starting icodextrin after ≥1 year on PD) compared with “early-starters” had more uncontrolled hypertension (38% versus 20%; P < 0.001), a higher antihypertensive agent requirement (68% versus 55%; P = 0.03) and an higher dialytic glucose exposure from baseline (5.4 versus 4.8 gm/kg per day; P = 0.05). Icodextrin use, both early and late, was independently associated with a positive linear increase in ultrafiltration sustained during follow-up compared with glucose use (β=0.27 and β=0.33, respectively; both P < 0.01). Peritonitis rates and dialysate leaks were similar between icodextrin and glucose groups. “Late-starters” had significantly increased risk of technique failure/death compared with “early-starters” (hazard ratio, 5.16; 95% confidence intervals, 1.57 to 17.0; P = 0.007). CONCLUSION: Icodextrin use improves ultrafiltration, but only early compared with delayed initiation conferred a five-fold higher likelihood of technique survival, better BP control, and preservation of RKF.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Khandelwal P, Borzych-Dużałka D, Hofstetter J, et al. Early-Start Versus Late-Start Icodextrin for Children Receiving Chronic Peritoneal Dialysis: Findings from the International Pediatric Peritoneal Dialysis Network. Clin J Am Soc Nephrol. 2025. PMID: 40924488. doi:10.2215/CJN.0000000837

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。